Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial.
- Authors:
- A Piskorz, KK Lin, JA Morris, E Mann, AM Oza, RL Coleman, DM O'Malley, M Friedlander, JM Cragun, L Ma, H Giordano, M Raponi, IA McNeish, EM Swisher, JD Brenton
- Journal:
- Journal of Clinical Oncology
- Citation info:
- 34(15_suppl):5549-5549
- Publication date:
- 20th May 2016
- Full text
- DOI